Stryker Corporation (SYK) - NYSE
  • Thu, Jul. 21, 4:46 PM
    • Stryker (NYSE:SYK) Q2 results ($M): Net Sales: 2,840 (+16.8%); Operating Expenses: 1,342 (+14.1%); Orthopedics: 1,082 (+4.6%); MedSurg: 1,258 (+33.8%); Neurotechnology and Spine: 500 (+9.3%).
    • Net Income: 380 (-3.1%); EPS: 1.00 (-2.9%).
    • 2016 Guidance: Organic sales growth: 6.0 - 6.5% from 5.5 - 6.5%; Non-GAAP EPS: $5.70 - 5.80 from $5.65 - 5.80.
    • Q3 Guidance: Non-GAAP EPS: $1.33 - 1.38.
    | Thu, Jul. 21, 4:46 PM | 1 Comment
  • Thu, Jul. 21, 4:37 PM
    • Stryker (NYSE:SYK): Q2 EPS of $1.39 beats by $0.02.
    • Revenue of $2.84B (+16.9% Y/Y) beats by $50M.
    • Shares -3.9%.
    • Press Release
    | Thu, Jul. 21, 4:37 PM
  • Wed, Jul. 20, 5:35 PM
    | Wed, Jul. 20, 5:35 PM | 13 Comments
  • Mon, Jun. 27, 11:16 AM
    | Mon, Jun. 27, 11:16 AM | 83 Comments
  • Fri, Apr. 29, 4:12 PM
    • Medtronic (MDT -0.8%) initiated with Buy rating and $93 (18% upside) price target by SunTrust Robinson Humphrey.
    • Celator Pharmaceuticals (CPXX +1.5%) initiated with Buy rating and $23 (53% upside) price target by Stifel Nicolaus.
    • Caladrius Biosciences (CLBS -1%) upgraded to Buy from Neutral by H.C. Wainwright with a price target of $1.25 (81% upside).
    • Insulet (PODD -0.6%) upgraded to Outperform from Market Perform by William Blair with a $40 (21% upside) price target.
    • Alexion Pharmaceuticals (ALXN -2.3%) upgraded to Outperform from Market Perform by BMO Capital with a $168 (21% upside) price target.
    • ResMed (RMD -1.2%) upgraded to Neutral from Underperform by Macquarie. Price target lowered to $57 (2% upside) from $65.
    • Stryker (SYK -0.5%) upgraded to Buy from Neutral by Sterne Agee CRT with $130 (19% upside) price target.
    • Jazz Pharmaceuticals (JAZZ -0.9%) upgraded to Buy from Neutral by SunTrust Robinson Humphrey. Price target raised to $200 (32% upside) from $164.
    • Rigel Pharmaceuticals (RIGL -1.7%) upgraded to Overweight from Neutral by JP Morgan with a $5 price target.
    • Novartis (NVS -1.1%) upgraded to Equal Weight from Underweight by Barclays.
    • Molina Healthcare (MOH -19.4%) downgraded to Neutral from Buy by UBS. Price target lowered to $54 (4% upside) from $76.
    • St. Jude Medical (STJ -2%) downgraded to Neutral from Overweight by JP Morgan. Price target raised to $82.50 (9% upside) from $66.
    • Stericycle (SRCL -21.5%) downgraded to Underperform from Sector Perform by RBC. Price target lowered to $96 (1% upside) from $119.
    • Sarepta Therapeutics (SRPT +2.8%) downgraded to Underperform from Hold by Jefferies with a price target of $7 (51% downside risk). Downgraded to Underweight from Neutral by Piper Jaffray. Price target lowered to $6 (57% downside risk) from $15.
    • Perrigo (PRGO +0.3%) downgraded to Neutral from Buy by BTIG Research. Priced target removed.
    • Trovagene (TROV -3.6%) downgraded to Hold from Buy by Cantor Fitzgerald with a $6 (50% upside) price target.
    • Community Health Systems (CYH -4.6%) downgraded to Underperform from Market Perform by Raymond James with a $19 (0% upside) price target.
    | Fri, Apr. 29, 4:12 PM | 5 Comments
  • Thu, Apr. 21, 10:23 AM
    • Stryker (SYK -0.3%) Q1 results: Revenues: $2,495M (+4.9%); R&D Expense: $159M (+4.6%); SG&A: $944M (+5.8%); Operating Income: $519M (+27.8%); Net Income: $402M (+79.5%); EPS: $1.07 (+84.5%); Non-GAAP EPS: $1.24 (+11.7%); Quick Assets: $6,976M (+106.5%).
    • Q2 Guidance: Non-GAAP EPS: $1.33 - 1.38.
    • 2016 Guidance: Organic sales growth: 5.5 - 6.5% from 5 - 6%; Non-GAAP EPS: $5.65 - 5.80 from $5.57 - 5.77.
    | Thu, Apr. 21, 10:23 AM | 4 Comments
  • Wed, Apr. 20, 4:49 PM
    • Stryker (NYSE:SYK): Q1 EPS of $1.24 beats by $0.04.
    • Revenue of $2.5B (+5.0% Y/Y) beats by $30M.
    • Press Release
    | Wed, Apr. 20, 4:49 PM | 1 Comment
  • Tue, Apr. 19, 5:35 PM
  • Fri, Apr. 15, 11:46 AM
    • Celator Pharmaceuticals (CPXX +4.6%) initiated with Buy rating and $24 (63% upside) price target by Needham.
    • Retrophin (RTRX -1.7%) initiated with Outperform rating and $25 (67%upside) price target by BMO Capital.
    • Fate Therapeutics (FATE -3.2%) initiated with Outperform rating and $4 (85% upside) price target by BMO Capital.
    • Tobira Therapeutics (TBRA +4.4%) initiated with Buy rating and $22 price target by H.C. Wainwright.
    • Wright Medical Group (WMGI +2.4%) initiated with Buy rating and $23 (21% upside) price target by Bank of America.
    • Cleveland Research rates UnitedHealth Group (UNH -0.9%) a Buy with a $155 (22% upside) price target; Anthem (ANTM -0.5%) a Buy with a $170 (20% upside) price target and Aetna (AET -0.4%) Neutral with a $120 (10% upside) price target.
    • Glaukos (GKOS +0.3%) initiated with Hold rating by Stifel.
    • Baxter International (BAX -0.3%) upgraded to Overweight from Neutral by Piper Jaffray. Price target raised to $58 (36% upside) from $39.
    • Baird upgrades Exactech (EXAC +0.7%) to Outperform from Neutral and raises the price target to $26 (18% upside) from $21. Stryker (SYK -0.9%) downgraded to Neutral from Outperform and raises the price target to $116 (6% upside) from $111.
    • Tenet Healthcare (THC -2.5%) upgraded to Positive from Neutral by Susquehanna.
    • Clovis Oncology (CLVS -1.5%) downgraded to Neutral from Overweight by JP Morgan. Price target lowered to $15 (7% upside) from $42.
    • AstraZeneca (AZN +0.3%) downgraded to Sell from Neutral by Goldman Sachs. Price target lowered to 3,700p (11% downside risk) from 4,400p.
    • Intercept Pharmaceuticals (ICPT +0.2%) downgraded to Underweight from Equal Weight by Morgan Stanley. Price target lowered to $80 (48% downside risk) from $100.
    | Fri, Apr. 15, 11:46 AM | 2 Comments
  • Fri, Mar. 18, 11:38 AM
    • Applied Genetic Technologies (AGTC +0.8%) initiated with Buy rating with $25 (85% upside) price target by Janney Capital.
    • Nomura's Ed Ridley has been busy in devices. He rates the following companies a Buy: Boston Scientific (BSX +1%) PT: 22 (22% upside); Zimmer Biomet Holdings (ZBH +0.3%) PT: 123 (18% upside); Edwards Lifesciences (EW +0.8%) PT: 101 (19% upside); St. Jude Medical (STJ +0.5%) PT: 64 (19% upside); Stryker (SYK +0.7%) PT: 115 (6% upside); Medtronic (MDT +0.8%) PT: 86 (13% upside). He rates C.R. Bard (BCR +0.7%) Neutral with a PT of $205 (5% upside).
    • Tesaro (TSRO +2.6%) initiated with Buy rating and $65 (46% upside) price target by Citigroup.
    • CRH Medical (CRHM +0.1%) initiated with Buy rating and $5 (48% upside) price target by Canaccord Genuity.
    • Evoke Pharma (EVOK) initiated with an Outperform rating and $16 (258% upside) price target by Northland Securities.
    • NanoString Technologies (NSTG -0.2%) initiated with Buy rating and $21 (31% upside) price target by Janney Capital.
    • AbbVie (ABBV +0.6%) initiated with Hold rating and $63 (13% upside) price target by Deutsche Bank.
    | Fri, Mar. 18, 11:38 AM | 5 Comments
  • Fri, Mar. 4, 8:31 AM
    • Stryker (NYSE:SYK) receives 510(k) clearance for its Tritanium PL Posterior Lumbar Cage for use in spinal fixation in patients with degenerative disc disease. The device is manufactured with a 3D printer using Tritanium, a novel highly porous titanium material that promotes bone in-growth and biologic fixation in spine applications.
    • The implant will be commercially available in Q2.
    | Fri, Mar. 4, 8:31 AM
  • Tue, Feb. 16, 8:30 AM
    • Stryker (NYSE:SYK) acquires vital signs monitor/defibrillator maker Physio-Control for $1.28B in cash from Bain Capital Private Equity. The deal should close in early Q2.
    • The company revises its 2016 EPS guidance upward to $5.57 - 5.77 (+8.8 - 12.7%). For 2017, it expects the Sage and Physio-Control transactions to add $0.15 - 0.18 to EPS.
    • Previously: Stryker buys ICU-focused Sage Products for $2.775B (Feb. 1)
    • Update: The transaction was completed on April 5.
    | Tue, Feb. 16, 8:30 AM
  • Mon, Feb. 1, 7:45 AM
    • Stryker (NYSE:SYK) acquires privately-held Cary, IL-based Sage Products, LLC for $2.775B in cash. Sage develops and commercializes disposable products used in the Intensive Care Unit (ICU) and MedSurg hospital unit settings. It posted $430M in sales last year.
    • The deal includes an anticipated future tax benefit of more than $500M.
    • Management will host a conference call this morning at 8:00 am ET to discuss the transaction.
    • Update: The transaction was completed on April 1.
    | Mon, Feb. 1, 7:45 AM | 1 Comment
  • Fri, Jan. 29, 12:03 PM
    • Medifast (MED +1.4%) initiated with Hold rating and $32 (10% upside) price target by Wunderlich.
    • Kite Pharma (KITE +4.1%) initiated with Buy rating and $70 (51% upside) price target by SunTrust Robinson Humphrey.
    • STAAR Surgical (STAA +0.3%) initiated with Hold rating by Benchmark.
    • Nektar Therapeutics (NKTR -2.4%) initiated with Buy rating and $21 (57% upside) price target by Janney Capital.
    • BioBlast Pharma (ORPN +7.7%) initiated with Buy rating and $25 (574% upside) price target by H.C. Wainwright.
    • CVS Health (CVS +1.3%) initiated with Outperform rating and $108 (14% upside) price target by Baird.
    • Walgreens Boots Alliance (WBA +1.1%) initiated with Outperform rating and $96 (22% upside) price target by Baird.
    • Intercept Pharma (ICPT +0.6%) upgraded to Equal Weight from Underweight by Morgan Stanley. Price target is $100 (0% upside).
    • Stryker (SYK +1.8%) upgraded to Buy from Hold by Brean Capital. Price target is $115 (16% upside).
    • Voyager Therapeutics (VYGR -0.7%) upgraded to Neutral from Sell by Chardan Capital. Price target lowered to $15 (50% upside) from $20.
    • Bristol-Myers Squibb (BMY +1.9%) upgraded to Buy from Hold by Berenberg. Price target raised to $77 (24% upside) from $74.
    • Oncomed Pharmaceuticals (OMED -0.3%) downgraded to Market Perform from Outperform by Leerink. Price target lowered to $11 (23% upside) from $27.
    • Regeneron Pharmaceuticals (REGN +0.6%) downgraded to Sell from Neutral by Chardan Capital. Price target lowered to $400 (4% downside risk) from $525.
    | Fri, Jan. 29, 12:03 PM | 13 Comments
  • Tue, Jan. 26, 6:50 PM
    • Along with earnings where it posted a higher profit that beat expectations, Stryker (NYSE:SYK) named a new chief financial officer.
    • Shares are up 0.7% after hours following the earnings beat.
    • Glenn Boehnlein is being promoted to the post, replacing retiring CFO William Jellison, effective April 1. Jellison has spent the last three years of a 36-year career with Stryker and will pursue getting more involved with board roles.
    • Boehnlein currently serves as group CFO for MedSurg & Neurotechnology.
    • Jellison will remain as CFO through the first quarter to ensure a smooth transition.
    • Previously: Stryker Q4 top line up 4%, non-GAAP EPS up 8% (Jan. 26 2016)
    • Previously: Stryker beats by $0.01, beats on revenue (Jan. 26 2016)
    | Tue, Jan. 26, 6:50 PM
  • Tue, Jan. 26, 4:31 PM
    • Stryker (NYSE:SYK) Q4 results ($M): Total Revenues: 2,715; Orthopedics: 1,145 (+3.2%); Medsurg: 1,087 (+3.1%); Neurotech & Spine: 483 (+6.4%).
    • Net Income: 522 (+100.8%); EPS: 1.38 (+106.0%); Non-GAAP EPS: 1.56 (+8.3%); CF Ops: 670 (-0.7%).
    • 2016 Guidance: Organic sales growth: 5 - 6%; Non-GAAP EPS: $5.50 - 5.70.
    • Q1 Guidance: Non-GAAP EPS: $1.17 - 1.22.
    | Tue, Jan. 26, 4:31 PM
Company Description
Stryker Corp. engages in the provision of medical technology products and services. It operates through the following segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides reconstructive and trauma implant systems. The Medsurg segment deals with... More
Sector: Healthcare
Industry: Medical Instruments & Supplies
Country: United States